GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00346442 | Cervix | CC | cellular response to UV | 20/2311 | 90/18723 | 6.05e-03 | 3.44e-02 | 20 |
GO:00507733 | Cervix | CC | regulation of dendrite development | 22/2311 | 103/18723 | 6.75e-03 | 3.71e-02 | 22 |
GO:00705343 | Cervix | CC | protein K63-linked ubiquitination | 14/2311 | 56/18723 | 6.93e-03 | 3.74e-02 | 14 |
GO:00486395 | Cervix | CC | positive regulation of developmental growth | 33/2311 | 174/18723 | 7.65e-03 | 4.07e-02 | 33 |
GO:00485886 | Cervix | CC | developmental cell growth | 42/2311 | 234/18723 | 7.88e-03 | 4.15e-02 | 42 |
GO:19038286 | Cervix | CC | negative regulation of cellular protein localization | 24/2311 | 117/18723 | 8.10e-03 | 4.23e-02 | 24 |
GO:0014065 | Cervix | CC | phosphatidylinositol 3-kinase signaling | 28/2311 | 144/18723 | 9.50e-03 | 4.72e-02 | 28 |
GO:00094163 | Cervix | CC | response to light stimulus | 54/2311 | 320/18723 | 1.03e-02 | 4.97e-02 | 54 |
GO:001003815 | Cervix | HSIL_HPV | response to metal ion | 36/737 | 373/18723 | 7.19e-07 | 3.65e-05 | 36 |
GO:003164715 | Cervix | HSIL_HPV | regulation of protein stability | 31/737 | 298/18723 | 8.69e-07 | 4.19e-05 | 31 |
GO:004217615 | Cervix | HSIL_HPV | regulation of protein catabolic process | 34/737 | 391/18723 | 1.41e-05 | 4.41e-04 | 34 |
GO:004573215 | Cervix | HSIL_HPV | positive regulation of protein catabolic process | 22/737 | 231/18723 | 1.24e-04 | 2.49e-03 | 22 |
GO:002260414 | Cervix | HSIL_HPV | regulation of cell morphogenesis | 25/737 | 309/18723 | 5.58e-04 | 7.93e-03 | 25 |
GO:001604914 | Cervix | HSIL_HPV | cell growth | 32/737 | 482/18723 | 2.87e-03 | 2.70e-02 | 32 |
GO:00301041 | Cervix | HSIL_HPV | water homeostasis | 8/737 | 64/18723 | 3.51e-03 | 3.15e-02 | 8 |
GO:007093613 | Cervix | HSIL_HPV | protein K48-linked ubiquitination | 8/737 | 65/18723 | 3.86e-03 | 3.35e-02 | 8 |
GO:003004813 | Cervix | HSIL_HPV | actin filament-based movement | 12/737 | 127/18723 | 4.37e-03 | 3.68e-02 | 12 |
GO:004580714 | Cervix | HSIL_HPV | positive regulation of endocytosis | 10/737 | 100/18723 | 6.00e-03 | 4.72e-02 | 10 |
GO:003030713 | Cervix | HSIL_HPV | positive regulation of cell growth | 14/737 | 166/18723 | 6.04e-03 | 4.75e-02 | 14 |
GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa05169110 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa04530110 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0453014 | Liver | NAFLD | Tight junction | 33/1043 | 169/8465 | 4.52e-03 | 4.12e-02 | 3.32e-02 | 33 |
hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0453015 | Liver | NAFLD | Tight junction | 33/1043 | 169/8465 | 4.52e-03 | 4.12e-02 | 3.32e-02 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NEDD4 | SNV | Missense_Mutation | novel | c.3618N>G | p.Asp1206Glu | p.D1206E | P46934 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
NEDD4 | SNV | Missense_Mutation | | c.3271N>G | p.His1091Asp | p.H1091D | P46934 | protein_coding | deleterious(0.03) | benign(0.05) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NEDD4 | SNV | Missense_Mutation | rs547250575 | c.280G>A | p.Glu94Lys | p.E94K | P46934 | protein_coding | deleterious(0.05) | probably_damaging(0.965) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEDD4 | SNV | Missense_Mutation | | c.1361N>A | p.Arg454Gln | p.R454Q | P46934 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NEDD4 | SNV | Missense_Mutation | | c.2611C>T | p.Pro871Ser | p.P871S | P46934 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
NEDD4 | SNV | Missense_Mutation | novel | c.154N>T | p.Met52Leu | p.M52L | P46934 | protein_coding | tolerated(0.3) | benign(0) | TCGA-E2-A576-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
NEDD4 | SNV | Missense_Mutation | rs369468383 | c.358G>T | p.Asp120Tyr | p.D120Y | P46934 | protein_coding | deleterious_low_confidence(0) | benign(0.347) | TCGA-GM-A2DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |
NEDD4 | SNV | Missense_Mutation | novel | c.3895G>C | p.Glu1299Gln | p.E1299Q | P46934 | protein_coding | tolerated(0.13) | benign(0.125) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEDD4 | insertion | Frame_Shift_Ins | novel | c.2747_2748insCCCTGTCTCTACTAAAAATGCAAAAAAAATTAGTTGGG | p.Lys916AsnfsTer26 | p.K916Nfs*26 | P46934 | protein_coding | | | TCGA-BH-A0H9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NEDD4 | insertion | Frame_Shift_Ins | novel | c.38_39insGATATTCTTGTGTTTCAGTGCATTTG | p.Ser14IlefsTer45 | p.S14Ifs*45 | P46934 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |